PATENT CLAIM ANALYSIS

Application Number: 16103865
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "135100"]

Abstract:
Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Claim (Index 30):
The method of  claim 22 , wherein the melanoma is Stage II, III or IV melanoma.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15592988', '15593915', '15592929', '15748284', '15480992']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7424177727231124
- 35 USC 102 Novelty (BERT): 0.5376178983397555
- Combined Prediction Score: 0.7219377852847767
- Mean Citation Score: 230.001678
- Max Citation Score: 385.25516
- Similarity Product: 188.7522527810955

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test